At present, immune checkpoint blockade therapy (PD-1, PD-L1, and CTLA4) has been successfully applied to renal cancer patients with certain results (Kammerer-Jacquet et al., 2019; Tucker and Rini, 2020). This evidence concerns the gene CTLA4 and renal carcinoma.